ScienceDaily | Published online: September 23 2016
A clinical trial for types of advanced cancer is the first of its kind to show that precision medicine — or tailoring treatment for individual people — can slow down the time it takes for a tumor to grow back, according to research presented at the Molecular Analysis for Personalized Therapy (MAP) conference.
Results from the trial, which took place at the Gustave Roussy Cancer Campus in Paris, found that 199 out of 1110 patients with advanced cancer, who had their genes mapped and their treatment tailored, had around 30 per cent longer before their cancer started growing again compared to any of the previous therapies the patients had tried. This ranged from between five and 32 months.
This trial involved patients who had no other treatment options left and who had already tried three or more cancer therapies. The team found potential faulty molecules to target for 411 of these patients and experimental drugs to hit the targets for 199 of these patients.
Read the full commentary here